enfortumab vedotin | Friends of Cancer Research

You are here

enfortumab vedotin

Sponsor: 
Astellas Pharma US, Inc. and Seattle Genetics, Inc.
Indication: 
Patients with locally advanced or metastatic urothelial carcinoma
Category: 
Year: 
2018
Date: 
Mar 26th
FDA Status: 
Designation Granted